BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ross JS, Ali SM, Fasan O, Block J, Pal S, Elvin JA, Schrock AB, Suh J, Nozad S, Kim S, Jeong Lee H, Sheehan CE, Jones DM, Vergilio JA, Ramkissoon S, Severson E, Daniel S, Fabrizio D, Frampton G, Miller VA, Stephens PJ, Gay LM. ALK Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. Oncologist 2017;22:1444-50. [PMID: 29079636 DOI: 10.1634/theoncologist.2016-0488] [Cited by in Crossref: 56] [Cited by in F6Publishing: 61] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu W, Liu HJ, Wang WY, Tang Y, Zhao S, Zhang WY, Yan JQ, Liu WP. Multisystem ALK-positive histiocytosis: a multi-case study and literature review. Orphanet J Rare Dis 2023;18:53. [PMID: 36915094 DOI: 10.1186/s13023-023-02649-x] [Reference Citation Analysis]
2 Galea LA, Hildebrand MS, Witkowski T, Joy C, McEvoy CR, Hanegbi U, Aga A. ALK-rearranged renal cell carcinoma with TPM3::ALK gene fusion and review of the literature. Virchows Arch 2023;482:625-33. [PMID: 36370168 DOI: 10.1007/s00428-022-03451-z] [Reference Citation Analysis]
3 Wang W, He L, Wu R, Yao J, Ma H, Cheng X, Wei A, Lian H, Wang D, Li Z, Wang T, Zhang R. Anaplastic lymphoma kinase positive histiocytosis presenting as hemocytopenia in an infant. Pediatr Blood Cancer 2023;70:e30010. [PMID: 36184781 DOI: 10.1002/pbc.30010] [Reference Citation Analysis]
4 Qi R, Yu Y, Shen M, Lv D, He S. Current status and challenges of immunotherapy in ALK rearranged NSCLC. Front Oncol 2022;12:1016869. [PMID: 36591504 DOI: 10.3389/fonc.2022.1016869] [Reference Citation Analysis]
5 Carballo EV, Pham TV, Turashvili G, Hanley K, Starbuck KD, Meisel JL. Recurrent uterine inflammatory myofibroblastic tumor previously managed as leiomyosarcoma has sustained response to alectinib. Gynecologic Oncology Reports 2022;43:101062. [DOI: 10.1016/j.gore.2022.101062] [Reference Citation Analysis]
6 Greenwell AM, Baughan S, Altinok D, Marupudi NI, Kupsky W, Kumar-sinha C, Gorsi HS. Lorlatinib for the Treatment of ALK Fusion–Positive Infant-Type Hemispheric Glioma: A Case Report. JCO Precision Oncology 2022. [DOI: 10.1200/po.22.00255] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Petrov I, Alexeyenko A. Individualized discovery of rare cancer drivers in global network context. Elife 2022;11:e74010. [PMID: 35593700 DOI: 10.7554/eLife.74010] [Reference Citation Analysis]
8 Li Y, Shi C, Wu Y, He M, Xia X, Liu J, Jiang Y. Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by Alectinib. Front Med 2022;9. [DOI: 10.3389/fmed.2022.840407] [Reference Citation Analysis]
9 Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low J, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC. Comprehensive Assessment of Anaplastic Lymphoma Kinase in Localized and Metastatic Prostate Cancer Reveals Targetable Alterations. Cancer Research Communications 2022;2:277-285. [DOI: 10.1158/2767-9764.crc-21-0156] [Reference Citation Analysis]
10 Iannantuono GM, Riondino S, Sganga S, Roselli M, Torino F. Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. Int J Mol Sci 2022;23:3995. [PMID: 35409355 DOI: 10.3390/ijms23073995] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Barreto-Coelho P, Rosenberg A, Subhawong T, Costa P, Espejo-Freire AP, Bialick S, Jonczak E, Trent JC, D'Amato GZ. Treatment of Disseminated Intravenous Leiomyomatosis With ALK Targeting Crizotinib: A Successful Case Report. JCO Precis Oncol 2022;6:e2100336. [PMID: 35108034 DOI: 10.1200/PO.21.00336] [Reference Citation Analysis]
12 Salgia SK, Govindarajan A, Salgia R, Pal SK. ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? JCO Precis Oncol 2021;5:767-70. [PMID: 34994610 DOI: 10.1200/PO.21.00078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kim H, Ahn S, Kang WK, Hong JY, Kim K. Two Gastric Cancers With Uncommon ALK Fusion Diagnosed With Comprehensive Panel Sequencing and Confirmed With Companion Diagnostic Assay. AJSP: Reviews and Reports 2022;27:9-12. [DOI: 10.1097/pcr.0000000000000480] [Reference Citation Analysis]
14 Chen W, Lin W, Wu L, Xu A, Liu C, Huang P. A Novel Prognostic Predictor of Immune Microenvironment and Therapeutic Response in Kidney Renal Clear Cell Carcinoma based on Necroptosis-related Gene Signature. Int J Med Sci 2022;19:377-92. [PMID: 35165523 DOI: 10.7150/ijms.69060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
15 Ohno H, Takeoka K, Kishimori C, Maekawa F, Nakagawa M, Fukutsuka K, Hayashida M, Honjo G. ALK-positive large B-cell lymphoma showing long-term response to conventional chemoradiotherapy. Tenri Med Bull 2021;24:100-107. [DOI: 10.12936/tenrikiyo.24-017] [Reference Citation Analysis]
16 Sugiyama M, Hirabayashi S, Ishi Y, Kikuchi J, Ishikura A, Motegi H, Ueda Y, Sawai S, Hara K, Terashita Y, Cho Y, Takakuwa E, Honda S, Yamaguchi S, Kinoshita I, Manabe A. Notable therapeutic response in a patient with systemic juvenile xanthogranuloma with KIF5B-ALK fusion. Pediatr Blood Cancer 2021;68:e29227. [PMID: 34245207 DOI: 10.1002/pbc.29227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Petrov I, Alexeyenko A. Individualized discovery of rare cancer drivers in global network context.. [DOI: 10.1101/2021.10.04.463007] [Reference Citation Analysis]
18 Torres GF, Bonilla CE, Buitrago G, Arrieta O, Malapelle U, Rolfo C, Cardona AF. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. Crit Rev Oncol Hematol 2021;166:103459. [PMID: 34461270 DOI: 10.1016/j.critrevonc.2021.103459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tomlins SA, Hovelson DH, Harms P, Drewery S, Falkner J, Fischer A, Hipp J, Kwiatkowski K, Lazo de la Vega L, Mitchell K, Reeder T, Siddiqui J, Vakil H, Johnson DB, Rhodes DR. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test. J Mol Diagn 2021;23:1515-33. [PMID: 34454112 DOI: 10.1016/j.jmoldx.2021.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Mondaca S, Lebow ES, Namakydoust A, Razavi P, Reis-Filho JS, Shen R, Offin M, Tu HY, Murciano-Goroff Y, Xu C, Makhnin A, Martinez A, Pavlakis N, Clarke S, Itchins M, Lee A, Rimner A, Gomez D, Rocco G, Chaft JE, Riely GJ, Rudin CM, Jones DR, Li M, Shaffer T, Hosseini SA, Bertucci C, Lim LP, Drilon A, Berger MF, Benayed R, Arcila ME, Isbell JM, Li BT. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions. Lung Cancer 2021;159:66-73. [PMID: 34311346 DOI: 10.1016/j.lungcan.2021.06.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
21 Subbiah V, Kuravi S, Ganguly S, Welch DR, Vivian CJ, Mushtaq MU, Hegde A, Iyer S, Behrang A, Ali SM, Madison RW, Venstrom JM, Jensen RA, McGuirk JP, Amin HM, Balusu R. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open 2021;6:100172. [PMID: 34242968 DOI: 10.1016/j.esmoop.2021.100172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Takeyasu Y, Okuma HS, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Shimoi T, Noguchi E, Arakawa A, Mori T, Sunami K, Kubo T, Kohno T, Akihiko Y, Yamamoto N, Yonemori K. Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors. JCO Precis Oncol 2021;5:PO. [PMID: 34036223 DOI: 10.1200/PO.20.00383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
23 Bai Y, Sun W, Niu D, Yang X, Diao X, Yu Y, Lin D. Localized ALK-positive histiocytosis in a Chinese woman: report of a case in the lung with a novel EML4-ALK rearrangement. Virchows Arch 2021. [PMID: 33825946 DOI: 10.1007/s00428-021-03092-8] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
24 Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori K, Yoshida A. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. Am J Surg Pathol 2021;45:347-55. [PMID: 32826530 DOI: 10.1097/PAS.0000000000001567] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
25 Sankar K, Nagrath S, Ramnath N. Immunotherapy for ALK-Rearranged Non-Small Cell Lung Cancer: Challenges Inform Promising Approaches. Cancers (Basel) 2021;13:1476. [PMID: 33806977 DOI: 10.3390/cancers13061476] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
26 Masood A, Christ T, Asif S, Rajakumar P, Gustafson BA, Shune LO, Salahudeen A, Nedvad D, Nanua S, Paner A, Kuzel TM, Levy M, Subramanian J, Raza S. Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition. NPJ Genom Med 2021;6:23. [PMID: 33731690 DOI: 10.1038/s41525-021-00186-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Wangsiricharoen S, Zhong M, Ranganathan S, Matoso A, Argani P. ALK-rearranged Renal Cell Carcinoma (RCC): A Report of 2 Cases and Review of the Literature Emphasizing the Distinction Between VCL-ALK and Non-VCL-ALK RCC. Int J Surg Pathol 2021;29:808-14. [PMID: 33729862 DOI: 10.1177/10668969211003660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Tarantino P, Mazzarella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev 2021;94:102169. [PMID: 33652262 DOI: 10.1016/j.ctrv.2021.102169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
29 Walsh EM, Xing D, Lippitt MH, Fader AN, Wethington SL, Meyer CF, Gaillard SL. Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. JCO Precis Oncol 2021;5:PO. [PMID: 34250413 DOI: 10.1200/PO.20.00189] [Reference Citation Analysis]
30 Novaes LAC, Sussuchi da Silva L, De Marchi P, Cavagna RO, de Paula FE, Zanon MF, Evangelista AF, Albino da Silva EC, Duval da Silva V, Leal LF, Reis RM. Simultaneous analysis of ALK, RET, and ROS1 gene fusions by NanoString in Brazilian lung adenocarcinoma patients. Transl Lung Cancer Res 2021;10:292-303. [PMID: 33569313 DOI: 10.21037/tlcr-20-740] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Kumar M, Kumar K, Singh HP, Nair S, Patel A, Kumar A, Soni S. Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer. South Asian J Cancer 2020;9:109-14. [PMID: 33354554 DOI: 10.1055/s-0040-1721191] [Reference Citation Analysis]
32 Qiu L, Weitzman SP, Nastoupil LJ, Williams MD, Medeiros LJ, Vega F. Disseminated ALK-positive histiocytosis with KIF5B-ALK fusion in an adult. Leuk Lymphoma 2021;62:1234-8. [PMID: 33353436 DOI: 10.1080/10428194.2020.1861273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Zhao G, Chen L, Xiao M, Yang S. Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib. Lung Cancer 2021;152:189-92. [PMID: 33419583 DOI: 10.1016/j.lungcan.2020.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Dagogo-Jack I, Ritterhouse LL. The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer. Transl Lung Cancer Res 2020;9:2557-70. [PMID: 33489818 DOI: 10.21037/tlcr-2019-cnsclc-09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
35 Hung YP, Dong F, Torre M, Crum CP, Bueno R, Chirieac LR. Molecular characterization of diffuse malignant peritoneal mesothelioma. Mod Pathol 2020;33:2269-79. [PMID: 32504035 DOI: 10.1038/s41379-020-0588-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
36 Zhou S, Liu W, Zhou C, Zhang L, Xie L, Xu Z, Wang L, Zhao Y, Guo L, Chen J, Ding L, Mao L, Tao Y, Zhang C, Ding S, Shao F. Mass balance, metabolic disposition, and pharmacokinetics of [14C]ensartinib, a novel potent anaplastic lymphoma kinase (ALK) inhibitor, in healthy subjects following oral administration. Cancer Chemother Pharmacol 2020;86:719-30. [PMID: 33044566 DOI: 10.1007/s00280-020-04159-0] [Reference Citation Analysis]
37 Syrykh C, Ysebaert L, Péricart S, Evrard SM, Meggetto F, Kanoun S, Brousset P, Laurent C. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib. Virchows Arch 2021;478:779-83. [PMID: 33011863 DOI: 10.1007/s00428-020-02937-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
38 Laskin J, Liu SV, Tolba K, Heining C, Schlenk RF, Cheema P, Cadranel J, Jones MR, Drilon A, Cseh A, Gyorffy S, Solca F, Duruisseaux M. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents. Ann Oncol 2020;31:1693-703. [PMID: 32916265 DOI: 10.1016/j.annonc.2020.08.2335] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 13.0] [Reference Citation Analysis]
39 Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat Rev 2020;86:102019. [PMID: 32251926 DOI: 10.1016/j.ctrv.2020.102019] [Cited by in Crossref: 120] [Cited by in F6Publishing: 134] [Article Influence: 40.0] [Reference Citation Analysis]
40 Ou SI, Zhu VW, Nagasaka M. Catalog of 5' Fusion Partners in ALK-positive NSCLC Circa 2020. JTO Clin Res Rep 2020;1:100015. [PMID: 34589917 DOI: 10.1016/j.jtocrr.2020.100015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
41 Dang AH, Tran VU, Tran TT, Thi Pham HA, Le DT, Nguyen L, Nguyen NV, Thi Nguyen TH, Nguyen CV, Le HT, Thi Nguyen ML, Le VT, Nguyen PH, Vo BT, Thi Dao HT, Nguyen LT, Van Nguyen TC, Bui QN, Nguyen LH, Nguyen NH, Thi Nguyen QT, Le TX, Do TT, Dinh KT, Do HN, Phan MD, Nguyen HN, Tran LS, Giang H. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep 2020;10:2707. [PMID: 32066856 DOI: 10.1038/s41598-020-59744-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
42 Wang L, Lui VWY. Emerging Roles of ALK in Immunity and Insights for Immunotherapy. Cancers (Basel) 2020;12:E426. [PMID: 32059449 DOI: 10.3390/cancers12020426] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
43 Fujiwara K, Ehara H, Kuwamoto S, Koyama S, Fukuhara T, Takeuchi H. Successful transoral videolaryngoscopic surgery for leiomyoma in the base of the tongue. Auris Nasus Larynx 2020;47:1074-8. [PMID: 32057524 DOI: 10.1016/j.anl.2020.01.010] [Reference Citation Analysis]
44 Angiolini M. The Role of Structural Biology in Kinase Inhibitor Drug Discovery Success. Structural Biology in Drug Discovery 2020. [DOI: 10.1002/9781118681121.ch16] [Reference Citation Analysis]
45 Yang J, Dong L, Du H, Li XB, Liang YX, Liu GR. ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review. Diagn Pathol 2019;14:112. [PMID: 31627758 DOI: 10.1186/s13000-019-0879-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
46 Gupta GK, Xi L, Pack SD, Jones JB, Pittaluga S, Raffeld M, Jaffe ES. ALK-positive histiocytosis with KIF5B-ALK fusion in an adult female. Haematologica 2019;104:e534-6. [PMID: 31371408 DOI: 10.3324/haematol.2019.230094] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
47 Nesline MK, DePietro P, Dy GK, Early A, Papanicolau-Sengos A, Conroy JM, Lenzo FL, Glenn ST, Chen H, Grand'Maison A, Boland P, Ernstoff MS, Puzanov I, Edge S, Akers S, Opyrchal M, Chatta G, Odunsi K, Frederick P, Lele S, Gardner M, Morrison C. Oncologist uptake of comprehensive genomic profile guided targeted therapy. Oncotarget 2019;10:4616-29. [PMID: 31384390 DOI: 10.18632/oncotarget.27047] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
48 Chang KTE, Tay AZE, Kuick CH, Chen H, Algar E, Taubenheim N, Campbell J, Mechinaud F, Campbell M, Super L, Chantranuwat C, Yuen ST, Chan JKC, Chow CW. ALK-positive histiocytosis: an expanded clinicopathologic spectrum and frequent presence of KIF5B-ALK fusion. Mod Pathol 2019;32:598-608. [PMID: 30573850 DOI: 10.1038/s41379-018-0168-6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 13.0] [Reference Citation Analysis]
49 Ou SI, Zhu VW. CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome. Lung Cancer 2019;130:201-7. [DOI: 10.1016/j.lungcan.2019.02.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
50 Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. Oncologist 2019;24:e1070-81. [PMID: 30902917 DOI: 10.1634/theoncologist.2018-0572] [Cited by in Crossref: 41] [Cited by in F6Publishing: 51] [Article Influence: 10.3] [Reference Citation Analysis]
51 Pal SK, Bergerot P, Dizman N, Bergerot C, Adashek J, Madison R, Chung JH, Ali SM, Jones JO, Salgia R. Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. Eur Urol 2018;74:124-8. [PMID: 29685646 DOI: 10.1016/j.eururo.2018.03.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
52 Zhao P, Peng L, Wu W, Zheng Y, Jiang W, Zhang H, Tong Z, Liu L, Ma R, Wang L, Yao M, Wang K, Fang W, Wu L. Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors. Oncologist 2019;24:449-54. [PMID: 30679319 DOI: 10.1634/theoncologist.2018-0439] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
53 Dagogo-Jack I, Rooney M, Nagy RJ, Lin JJ, Chin E, Ferris LA, Ackil J, Lennerz JK, Lanman RB, Gainor JF, Shaw AT. Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. J Thorac Oncol 2019;14:816-24. [PMID: 30664990 DOI: 10.1016/j.jtho.2019.01.009] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 13.3] [Reference Citation Analysis]
54 Marks EI, Pamarthy S, Dizon D, Birnbaum A, Yakirevich E, Safran H, Carneiro BA. ROS1-GOPC/FIG: a novel gene fusion in hepatic angiosarcoma. Oncotarget. 2019;10:245-251. [PMID: 30719217 DOI: 10.18632/oncotarget.26521] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
55 Hainsworth JD, Greco FA. Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine. Am Soc Clin Oncol Educ Book 2018;38:20-5. [PMID: 30231392 DOI: 10.1200/EDBK_100014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
56 Hung YP, Sholl LM. Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. Adv Anat Pathol 2018;25:374-86. [PMID: 30188361 DOI: 10.1097/PAP.0000000000000206] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
57 Clark TA, Chung JH, Kennedy M, Hughes JD, Chennagiri N, Lieber DS, Fendler B, Young L, Zhao M, Coyne M, Breese V, Young G, Donahue A, Pavlick D, Tsiros A, Brennan T, Zhong S, Mughal T, Bailey M, He J, Roels S, Frampton GM, Spoerke JM, Gendreau S, Lackner M, Schleifman E, Peters E, Ross JS, Ali SM, Miller VA, Gregg JP, Stephens PJ, Welsh A, Otto GA, Lipson D. Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. J Mol Diagn. 2018;20:686-702. [PMID: 29936259 DOI: 10.1016/j.jmoldx.2018.05.004] [Cited by in Crossref: 114] [Cited by in F6Publishing: 122] [Article Influence: 22.8] [Reference Citation Analysis]
58 Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA. Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clin Cancer Res 2018;24:2732-9. [PMID: 29559559 DOI: 10.1158/1078-0432.CCR-18-0332] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]